Arabic Arabic English English French French German German
dark

Tenaya Therapeutics Provides 2022 Business Updates

Tenaya Therapeutics, Inc. today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC) due to PKP2 gene mutation. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

Next Post

MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference

Related Posts
Total
0
Share